Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Lock-Up Expiration Hell Portfolio -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (947)	3/11/2004 6:25:59 PM
From: keokalani'nui	Respond to of 1005

Cotherics S-1, CTRX Overview We are a biopharmaceutical company focused on licensing, developing and commercializing therapeutic products for the treatment of cardiopulmonary and infectious diseases. Ventavis, our lead product candidate, is an inhaled prostacyclin analogue for the treatment of pulmonary arterial hypertension, or PAH, that we believe offers advantages over existing therapies. Ventavis is currently marketed in various European countries by Schering AG and we licensed the exclusive U.S. rights to Ventavis from Schering AG in October 2003. We plan to file a New Drug Application, or NDA, for Ventavis with the U.S. Food and Drug Administration, or FDA, in 2004 based primarily on the results of the clinical trials conducted by Schering AG. In addition, we plan to investigate the use of Ventavis in combination therapy with a currently approved treatment for PAH in order to expand the commercial potential of Ventavis. We are also developing CTX-100 for the treatment of emphysema. We believe that our in-depth understanding of the biology of cardiopulmonary and infectious diseases, combined with our management’s development and commercialization experience, will enable us to continue to identify and license or acquire product candidates in our target disease markets.